Stemedica Cell Technologies, Inc.

38 articles with Stemedica Cell Technologies, Inc.

• FDA Grants IND Approval for Phase II Clinical Trial Using Stemedica's itMSC Therapy for COVID-19 Patients

  9/28/2020

  Stemedica Cell Technologies, Inc. has received U.S. FDA Investigational New Drug approval for "A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients with Moderate to Severe Lung Injury due to COVID-19."

• First COVID-19 Patient Treated Under Emergency Use IND At Providence Saint John's Health Center Using Stemedica Ischemia-Tolerant Allogeneic Mesenchymal Bone Marrow Cells

  4/20/2020

  A single patient, emergency Investigational New Drug use was cleared by the U.S. Food and Drug Administration for the treatment of severe lung injury due to COVID-19 at the Providence Saint John's Health Center, Santa Monica, CA with intravenous administration of ischemia-tolerant allogeneic mesenchymal bone marrow cells manufactured by Stemedica Cell Technologies, Inc.

• 

  Clinical Catch-Up for September 31-October 4

  10/7/2019

  It was another busy week for clinical trials. Here’s a look.

• Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in Peer-Reviewed Stroke Journal

  9/30/2019

  Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published in Stroke entitled "Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke."

• CryoPort Expands Agreement With Stemedica Cell Technologies, Inc. To Support A Phase II Clinical Trial To Assess A Stem Cell Therapy For The Treatment Of Alzheimer's Disease

  8/11/2016

• Stemedica Cell Technologies, Inc. Begins First Clinical Trials In The U.S. Using Adult Allogeneic Stem Cells To Treat Alzheimer's Disease

  7/27/2016

• FDA Grants IND Approval To Stemedica Cell Technologies, Inc. For A Traumatic Brain Injury Phase Ila Clinical Trial

  5/18/2016

• Stemedica Cell Technologies, Inc. Announces Completion Of Enrollment In Phase I/Ila Clinical Trial For Ischemic Stroke

  1/27/2016

• Stemedica Cell Technologies, Inc. Establishes Stem Cell Commercial Manufacturing Facility

  11/10/2015

• CryoPort, Inc. Supports Stemedica Cell Technologies, Inc.'s Ischemic-Tolerant Stem Cell Product Lines

  8/18/2015

• Stemedica Cell Technologies, Inc. Awarded U.S. Patent For Transgenic Therapeutic Stem Cells

  8/13/2015

• Stemedica Cell Technologies, Inc. Release: FDA Grants IND Approval For Phase Iia Clinical Trial Using Stemedica's itMSC Therapy To Treat Alzheimer's Disease

  6/9/2015

• Stemedica Cell Technologies, Inc. Obtains An Exclusive Worldwide License For Stem Cell Stabilization And Preservation Technologies

  3/24/2015

• Novastem Treats First Patient Using Stemedica Cell Technologies, Inc.'s Mesenchymal And Neural Stem Cell Combination Therapy For Ischemic Stroke

  12/24/2014

• Stemedica Cell Technologies, Inc. Release: WSCS14 Poster Forum Winners Announced

  12/8/2014

• Stemedica Cell Technologies, Inc. Secures U.S. Patent To Use Multiple Stem Cell Lines Simultaneously To Treat Ischemic Stroke

  10/1/2014

• Stemedica Cell Technologies, Inc. Earns U.S. Patent For Cellular Scaffold Enhanced By Stem Cell Factors

  6/10/2014

• Indonesia’s BPOM Grants IND Approval For SCI To Conduct A Phase 2 Clinical Trial Using Stemedica Cell Technologies, Inc.’s Mesenchymal Stem Cells To Treat Acute Myocardial Infarction

  5/27/2014

• President Of Leading South Korean Biopharmaceutical Company Green Cross Joins Stemedica Cell Technologies, Inc.'s Board Of Directors

  4/22/2014

• Stemedica Cell Technologies, Inc. Appoints National Institutes of Health (NIH) Center For Regenerative Medicine Founding Director Dr. Mahendra Rao To Its Scientific And Medical Advisory Board

  4/9/2014